3.01

3.08% 0.09

Pre-market: 2.93 -0.08 -2.66%

Vistagen Therapeutics Inc (VTGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vistagen Therapeutics Inc stock is traded at $3.01, with a volume of 214.73K. It is up +3.08% in the last 24 hours and up +20.40% over the past month. Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Previous Close:

$2.92

Open:

$2.95

24h Volume:

214.73K

Relative Volume:

0.77

Market Cap:

$83.81M

Revenue:

$875.70K

Net Income/Loss:

$-39.57M

P/E Ratio:

-2.2424

EPS:

-1.3423

Net Cash Flow:

$-33.65M

1W Performance:

+5.99%

1M Performance:

+20.40%

6M Performance:

-17.76%

1Y Performance:

-34.85%

1-Day Range:

$2.90

$3.05

1-Week Range:

$2.83

$3.10

52-Week Range:

$2.22

$5.74

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name

Vistagen Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

650-577-3600

Address

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

@vistagen

Next Earnings Date

2024-11-07

Latest SEC Filings

VTGN's Discussions on Twitter

Compare VTGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTGN Vistagen Therapeutics Inc	3.01	83.81M	875.70K	-39.57M	-33.65M	-1.3423
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-07-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Upgrade	Maxim Group	Hold → Buy
Jul-22-22	Downgrade	Jefferies	Buy → Hold
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
May-20-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Initiated	Jefferies	Buy
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy
Feb-08-18	Reiterated	Chardan Capital Markets	Buy
Mar-28-17	Initiated	Maxim Group	Buy

View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

01:15 AM

Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World

01:15 AM

Jan 16, 2025

Jane Street Group LLC Purchases Shares of 19,659 Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jan 16, 2025

Jan 15, 2025

Vistagen reports positive outcomes from Phase IIA cancer cachexia trial - Yahoo Finance

Jan 15, 2025

Jan 14, 2025

Vistagen reports promising PH284 nasal spray study By Investing.com - Investing.com Canada

Jan 14, 2025

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia - sharewise

Jan 14, 2025

Vistagen reports promising PH284 nasal spray study - Investing.com

Jan 14, 2025

Jan 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Geode Capital Management LLC - Defense World

Jan 11, 2025

Jan 10, 2025

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder - sharewise

Jan 10, 2025

Dec 27, 2024

HighTower Advisors LLC Purchases New Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Dec 27, 2024

Dec 19, 2024

VTGN stock touches 52-week low at $2.38 amid market challenges - Investing.com India

Dec 19, 2024

Dec 18, 2024

VTGN stock touches 52-week low at $2.38 amid market challenges By Investing.com - Investing.com South Africa

Dec 18, 2024

Dec 12, 2024

Mental Disorder Treatment Market Innovations and Key Players: - openPR

Dec 12, 2024

PD-LID Market Growth to Accelerate in Forecast Period - openPR

Dec 12, 2024

Dec 11, 2024

VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 11, 2024

Dec 10, 2024

VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges - Investing.com

Dec 10, 2024

Nov 30, 2024

VTGN (Vistagen Therapeutics) Inventory Turnover : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 30, 2024

Nov 27, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Great Point Partners LLC - MarketBeat

Nov 27, 2024

Nov 26, 2024

Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World

Nov 26, 2024

Nov 22, 2024

VTGN Stock Touches 52-Week Low at $2.51 Amid Market Challenges - Investing.com India

Nov 22, 2024

Nov 21, 2024

Anxiety drug trials keep Stifel optimistic on VistaGen stock's upside potential - Investing.com Canada

Nov 21, 2024

Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World

Nov 21, 2024

Nov 17, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World

Nov 17, 2024

Nov 15, 2024

Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely - Simply Wall St

Nov 15, 2024

Nov 14, 2024

Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online

Nov 14, 2024

Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan

Nov 14, 2024

Nov 11, 2024

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Nov 11, 2024

Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat

Nov 11, 2024

Nov 08, 2024